Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients

PurposeThe purpose of this study was to investigate the clinical features of epithelial ovarian cancer (EOC) patients according to BRCA1/2 mutation status (mutation, variant of uncertain significance [VUS], or wild type). Materials and MethodsWe analyzed 116 patients whose BRCA1/2 genetic test results were available for mutation type and clinical features, including progression-free survival (PFS), overall survival (OS), and response rate.These characteristics were compared according to BRCA1/2 mutation status. ResultsThirty-seven (37/116, 31.9%)BRCA1/2 mutations were identified (BRCA1, 30; BRCA2, 7).Mutation of c.3627_3628insA (p.Leu1209_Glu1210?fs) in BRCA1 was observed in five patients (5/37, 13.5%).Twenty-five patients had BRCA1/2 VUSs (25/116, 21.6%).Personal histories of breast cancer were observed in 48.6% of patients with BRCA1/2 mutation (18/37), 16.0% of patients with BRCA1/2 VUS (4/25), and 7.4% of patients with BRCA wild type (4/54) (p < 0.001).Patients with BRCA1/2 mutation showed longer OS than those with BRCA1/2 wild type (p=0.005).No significant differences were detected in PFS, OS, or response rates between patients with BRCA1/2 VUS and BRCA1/2 mutation (p=0.772,p=0.459, and p=0.898, respectively). ConclusionPatients with BRCA1/2 mutation had longer OS than those with BRCA1/2 wild type.Patients with BRCA1/2 mutation and BRCA1/2 VUS displayed similar prognoses.